 Interleukin-2
"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.502 D12.644.276.374.480.372 D12.776.467.374.465.502 D12.776.467.374.480.372 D23.529.374.465.502 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1987 | 0 | 1 | 1 | | 1990 | 0 | 1 | 1 | | 1991 | 0 | 1 | 1 | | 1993 | 1 | 1 | 2 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 5 | 5 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 4 | 1 | 5 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 3 | 0 | 3 | | 2002 | 4 | 1 | 5 | | 2003 | 5 | 2 | 7 | | 2004 | 1 | 0 | 1 | | 2005 | 3 | 2 | 5 | | 2006 | 1 | 3 | 4 | | 2007 | 3 | 3 | 6 | | 2008 | 3 | 2 | 5 | | 2009 | 2 | 1 | 3 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 1 | 2 | 3 | | 2013 | 1 | 1 | 2 | | 2014 | 1 | 0 | 1 | | 2016 | 0 | 2 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labão-Almeida C, Ali LR, Quijano-Rubio A, Ruterbusch M, Leung I, Biary T, Crowley SJ, Marcos E, Walkey CD, Weitzner BD, Pardo-Avila F, Castellanos J, Carter L, Stewart L, Riddell SR, Pepper M, Bernardes GJL, Dougan M, Garcia KC, Baker D. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019 01; 565(7738):186-191.
-
Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
-
Desai SN, Dodge JL, Landay AL, Glesby MJ, Latham PS, Villacres MC, French AL, Gange SJ, Greenblatt RM, Peters MG. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore). 2016 Aug; 95(33):e4483.
-
Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):163-71.
-
Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep; 37(7):360-5.
-
Gunawardane ND, Vaghani SP, Kuzel TM, Cotliar JA. Acute generalized exanthematous pustulosis in a patient receiving high-dose recombinant interleukin-2. J Am Acad Dermatol. 2013 Oct; 69(4):e183-4.
-
Šedý JR, Bjordahl RL, Bekiaris V, Macauley MG, Ware BC, Norris PS, Lurain NS, Benedict CA, Ware CF. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. J Immunol. 2013 Jul 15; 191(2):828-36.
-
Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology. 2013; 84(2):123-6.
-
Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother. 2012 Oct; 35(8):629-40.
-
Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacek AT, O'Sullivan JA, Varanasi V, Williams JW, Jagoda MC, Bellavance EC, Marzo AL, Thomas PG, Zafirova B, Polic B, Al-Harthi L, Sperling AI, Guevara-Patiño JA. NKG2D signaling on CD8? T cells represses T-bet and rescues CD4-unhelped CD8? T cell memory recall but not effector responses. Nat Med. 2012 Feb 26; 18(3):422-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|